Introduction
In the UK each year over 8,000 people are diagnosed with esophageal cancer.(1) The prognosis is poor (5 year survival rates are 8%) (2) , and so research into new treatment strategies are warranted. Although mainly used to treat hypercholesterolaemia,(3) there is increasing evidence from both cell lines and animal models that statins have antitumor properties. (4) Preclinical studies have shown, by inhibiting a rate-limiting enzyme (3- hydroxy-3-methylglutaryl Coenzyme A reductase) in the mevalonate pathway, statins induce apoptosis and inhibit angiogenesis. (5, 6) Of specific relevance to esophageal cancer, Ogunwobi et al showed that statins inhibit proliferation and induce apoptosis in esophageal adenocarcinoma cell lines. (7) In humans, recent epidemiological studies have shown reductions in esophageal cancer risk in statin users. (8) Despite these promising findings, there has been little research into the effect of statin use after diagnosis on survival from esophageal cancer. The only previous epidemiological study to investigate statin use after diagnosis in esophageal cancer patients concluded that statins were associated with large and significant reductions in cancer-specific and all-cause mortality. (9) The association between statin use and esophageal cancer-specific mortality is of importance because it will inform the decision to conduct clinical trials of statins as adjuvant cancer therapy in esophageal cancer patients. Therefore, to clarify this association we investigated whether statin use after cancer diagnosis was associated with reduced esophageal cancerspecific and all-cause mortality in a population-based cohort of esophageal cancer patients.
Materials and methods

Data source
The study utilised linkages between national datasets from Scotland including the Scottish Cancer Registry (SMR06), the Prescribing Information System, the General / Acute Inpatient 
Study population
A cohort of newly diagnosed esophageal cancer patients was identified on the basis of a Scottish Cancer Registry recorded primary diagnosis of esophageal cancer (ICD code C15) between Jan 2009 and Dec 2012. Cohort members with previous Scottish Cancer Registry cancer diagnosis (after January 1999), apart from in situ neoplasms and non-melanoma skin cancers, were excluded.
Deaths were identified from National Records of Scotland with coverage up to 1st January 2015 (or from Scottish Cancer Registry death records) with esophageal cancer-specific deaths defined as those with underlying cause of death esophageal cancer (C15), gastric cancer (C16), or malignant neoplasm of other and ill-defined digestive organs (C26). Patients who died in the first 6 months after their esophageal cancer diagnosis were excluded because it seemed unlikely that post diagnostic medication use could influence such deaths, therefore the follow-up date started 6 months after diagnosis. The patients were followed from 6 months after date of esophageal cancer diagnosis to death, the date they left Scotland or 1 st January 2015.
Study design
Exposure data: Statins dispensed in the community (identified from the Prescribing Information System) consisted of all medications in the Statins section of the British National Formulary (Section 2.12).(10) A quantity of 28 tablets was assumed for the less than 0.1% of prescriptions where quantity was assumed incorrect. Daily defined doses (DDD) were calculated on the basis of quantity and strength (as defined by the World Health Organisation(11)). Statin use was investigated as a time varying covariate.(12) Patients were initially considered non-users and then users thereafter for the remainder of follow-up, after a lag of 6 months (though this was varied in sensitivity analyses) which was applied to all individuals. The use of a lag is recommended (13) and in this study the lag, in effect, removed prescriptions in the 6 month period prior to death or end of follow-up, the former of which as these may reflect end of life treatment. The study design is described in Figure 1 .
Covariates
Data available from the Scottish Cancer Registry included morphology (from ICD-O codes, allowing esophageal adenocarcinoma and squamous cell carcinoma to be identified), histological grade and surgery, chemotherapy and radiotherapy in the six months after diagnosis. Comorbidities that contribute to the Charlson index were determined prior to diagnosis based upon ICD10 diagnosis codes, as described previously (14) in Scottish hospital inpatient (SMR01) and outpatient data (SMR00). A deprivation measure was determined using the 2009 Scottish Index of Multiple Deprivation based upon postcode of residence. (14, 15) 
Statistical analysis
In the main analysis, time-dependent Cox regression models were used to calculate hazard ratios (HRs) for esophageal cancer-specific death and 95% confidence intervals (95% CIs) for statin users compared with non-users using a time varying covariate, as described previously. Adjusted analyses were conducted including the following potential confounders: sex, age, year of diagnosis, deprivation (in fifths), surgery (within 6 months), radiotherapy (within 6 months), chemotherapy (within 6 months), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin usage (as time varying covariate). A dose-response analysis was conducted with individuals considered non-users prior to 6 months after first use, a short term user between 6 months after first use and 6 months after the 12 th prescription and a longer term user after this time. Analyses were repeated for all-cause mortality. Log-log plots were produced to check the proportional hazard assumptions. The main analysis was repeated comparing simvastatin users to simvastatin non-users (and a separate analysis was conducted comparing simvastatin users to statin non-users but gave similar results, not shown). Finally, an analysis was conducted comparing statin users to statin non-users in the year before diagnosis (excluding patients diagnosed in 2009 for whom a full year of prescription records prior to diagnosis may not be available), not excluding deaths after diagnosis. An adjusted analysis was first conducted omitting cancer treatment from adjustments for potential confounders to avoid over-adjustment (17, 18) as these could be on the causal pathway for esophageal cancer-specific mortality, but subsequently, a fully adjusted analysis was conducted including these variables.
Results
Patient cohort
There were 3,463 esophageal cancer patients diagnosed 2009 to 2012. Overall, 414 were excluded because of a previous cancer diagnosis, and 17 were removed because they died on the date of their cancer diagnosis, therefore 3,032 were eligible for analysis. The main analysis of post diagnosis statin use contained 1,921 esophageal cancer patients (because 1,128 esophageal cancer patients were excluded because they died within 6 months) in whom there was a mean of 2 years of follow-up (min=0.5 and maximum=6 years) and there were 1,502 deaths due to any cause, 1,373 of which were due to esophageal cancer.
Patient characteristics by statin use are shown in Table 1 . Statin users were more likely to be male, older and diagnosed more recently. A greater proportion of statin users compared with non-users had esophageal adenocarcinoma (60% versus 55%, respectively) whilst a slightly smaller proportion had poorly differentiated tumours (44% versus 47%, respectively). Statin users were more likely to have radiotherapy and less likely to have surgery or chemotherapy compared with non-users. Statin users were more likely to have comorbidities (particularly for cerebrovascular disease, diabetes, stroke and myocardial infarction) and use low dose aspirin. Table 2 shows the main findings. There was little evidence of a reduction in esophageal cancer-specific mortality in statin users after diagnosis (adjusted HR=0.93, 95% CI, 0.81, 1.07, respectively). There was also little evidence of a dose-response association when exposure was investigated by number of prescriptions. There was also no association when simvastatin was investigated (adjusted HR=1.02, 95% CI 0.89, 1.17). Similar associations were observed for all-cause mortality. Table 3 shows subgroup and sensitivity analyses. The main findings were similar when including cancers of the cardia (C16.0) and additionally adjusting for grade. There was little evidence of an association after adjusting for statin use before diagnosis (HR=0.86 95% CI 0.68, 1.08) or when restricting to statin users in the year prior to diagnosis (HR=0.84 95% CI 0.64, 1.10) or statin non-users in the year prior to diagnosis (HR=0.69 95% CI 0.35, 1.37).
Association between statin use after diagnosis and survival
Subgroup and sensitivity analyses
Subgroup analyses did not reveal marked differences in the association between statin use and esophageal cancer-specific mortality by gender or histologic subtypes (in squamous cell carcinoma and esophageal adenocarcinoma the associations were adjusted HR=0.94, 95% CI 0.73, 1.21 and adjusted HR=0.90, 95% CI 0.75, 1.08, respectively). In a simplified analysis comparing statin users in the first 6 months versus non-users (restricted to individuals living 6 months), the association was similar (adjusted HR=0.90, 95% CI 0.79, 1.03). Associations between statins and esophageal cancer-specific mortality were apparent when no lag (adjusted HR=0.68 95% CI 0.61, 0.76) or a 3 month lag was used (adjusted HR=0.80 95% CI 0.70, 0.90) but when longer lags of 6 months (as in the main analysis) or 12 months were used the associations were attenuated.
Association between statin use before diagnosis and survival
Overall, statin users before diagnosis had a 12% reduction in the rate of esophageal cancerspecific mortality (fully adjusted HR=0.88, 95% CI 0.79, 0.99) compared with statin nonusers following adjustment for confounders, Table 4 . Comparable associations were observed for all-cause mortality.
Discussion
In this population-based cohort, there was little evidence of an association between statin use after diagnosis of esophageal cancer and esophageal cancer-specific mortality. There was however a weak association between statin use in the year prior to diagnosis and esophageal cancer-specific mortality.
The only previous study (9) to investigate statin use after diagnosis and esophageal cancerspecific mortality used Clinical Practice Research Datalink data from England (based upon GP prescribing data and linked cancer registry data and national mortality data). This study concluded that statins were associated with large and significant reductions in esophageal cancer specific mortality. This conclusion was based upon an unlagged analysis in which statin use was associated with marked reductions in esophageal cancer-specific mortality (adjusted HR=0.62 95% CI 0.44, 0.86) and this association was similar when the authors used a 3 month lag (adjusted HR=0.66, 95% CI 0.41, 1.07, respectively). We observed a similar association in unlagged analysis (adjusted HR=0.68 95% CI 0.61, 0.76), but in contrast to their study, this was markedly attenuated when using a 3 month lag (adjusted HR=0.80 95% CI 0.70, 0.90) and in our main analysis (using a 6 month lag) there was no association (adjusted HR=0.93 95% CI 0.81, 1.07). The use of a lag is recommended to reduce reverse causality (13) which could arise if esophageal cancer patients were less likely to start statins when they were obviously close to death. Observational studies in colorectal cancer patients have shown marked reductions in statin prescribing in the six months prior to death and stated that inclusion of an exposure lag is vital to account for reverse causation. (19) The use of a longer lag explains the difference in conclusion between our studies but the reason for the difference in the magnitude of the association when using a 3 month lag remains unclear.
Our findings of an approximate 10% reduction in cancer-specific and all-cause mortality in esophageal cancer patients who use statins before diagnosis is consistent with a nationwide Danish study which observed a reduction in cancer-specific mortality of around 20% with statin use before diagnosis (adjusted HR = 0.81, 95% CI 0.69, 0.95) (17, 18) and the previously mentioned English study which observed around a 10% reduction in cancerspecific and all-cause mortality (adjusted HR=0.91, 95% CI 0.71, 1.16 and adjusted HR=0.86, 95% CI 0.55, 1.20, respectively). The cause of this reduction is unknown, and may not be causal, but could reflect the anticancer properties of statins on the developing esophageal cancer, seen in preclinical studies, which have shown that statins inhibit proliferation, and reduce apoptosis in esophageal adenocarcinoma cell lines. (7) The clinical utility of this finding is unclear as it is difficult to intervene prior to esophageal cancer diagnosis. Medication use prior to cancer diagnosis may be subject to a healthy user effect, whereby those with lesser disease experiencing less severe symptoms may be more likely to keep using the medications, compared with patients with more advanced disease discontinuing the drug. (20) Our study has many strengths. It is the largest cohort to investigate statin use after diagnosis and esophageal cancer-specific mortality in esophageal cancer patients. Despite this, we cannot rule out a weak protective effect of statins after diagnosis that we could not detect as statistically significant due to lack of power. The study utilised high quality data sources from the Scottish Cancer Registry (allowing a population based cancer cohort to be identified), the Prescribing Information System (providing detailed information on the timing of medication use allowing temporal associations to be investigation) and the National Records of Scotland Death Records (allowing deaths to be captured comprehensively). Our main analysis was conducted using a lag of 6 months, although a lag is recommended,(13) a weakness of this approach is that it will by necessity exclude patients who lived less than 6 months after esophageal cancer diagnosis, therefore restricting the generalizability of results.
Misclassification of statin use by over the-counter use is likely to be limited as only low dose 10mg simvastatin is available in Scotland and this accounts for a very small proportion of statin use; a UK study recently estimated less than 1% of the population obtain statins the over the counter. (21) Similarly, there is the possibility of over-the-counter use of aspirin, which was included as a covariate, but previous studies suggest in this age group 70 to 95% of use will be captured by prescriptions. (22, 23) However, misclassification of statin/aspirin use by non-compliance is possible. As with all observational studies there is the possibility of residual confounding, in this instance potential confounders include stage, smoking, alcohol and exercise.
In conclusion, in this population based cohort study of esophageal cancer patients, we found little evidence of an association between statin therapy after diagnosis and improved survival. Statin use in the year prior to diagnosis. c Refers to aspirin use in the 6 months after diagnosis in the first four columns and aspirin use in the year prior to diagnosis in the next four columns. Includes cancer of the cardia (C16.0) in esophageal cancer definition. c Simplified analysis, comparing statin users to statin non-users in the 6 months after diagnosis in individuals living more than 6 months after cancer diagnosis, adjusted for all confounders in a but other medication use also restricted to first 6 months after diagnosis. d Time varying covariate analysis (using model in a ) varying the duration of lag from no lag (not removing any deaths after diagnosis), to a 3 month lag (removing deaths in the first 3 months after diagnosis), a 6 month lag (removing deaths in the first 6 months after diagnosis) or a 12 month lag (removing deaths within the first 12 months after diagnosis). e Statin users versus non-users after diagnosis using model in a, stratified by statin use in the year prior to diagnosis, restricted to esophageal cancer cases diagnosed 2010 to 2012. f Statin users versus non-users after diagnosis using model in a, adjusting for statin use in the year prior to diagnosis, restricted to esophageal cancer cases diagnosed 2010 to 2012. 
